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Abstract
The objectives of this analysis were to compare the ability of fasting plasma glucose (FPG), post 
oral load plasma glucose (2hPG), and hemoglobin A1c (HbA1c) to identify U.S. Hispanic/Latino 
individuals with prediabetes, and to assess its cardiovascular risk factor correlates.
This is a cross-sectional analysis of baseline data from 15,507 adults without self-reported 
diabetes mellitus from six Hispanic/Latino heritage groups, enrolled in the Hispanic Community 
Health Study/Study of Latinos, which takes place in four U.S. communities. The prevalence of 
prediabetes was determined according to individual or combinations of ADA-defined cut points: 
FPG = 5.6–7.0 mmol/L, 2hPG = 7.8–11.1 mmol/L, and HbA1c = 5.7%-6.4% (39–46 mmol/mol). 
The sensitivity of these criteria to detect prediabetes was estimated. The prevalence ratios (PRs) 
for selected cardiovascular risk factors were compared among alternative categories of prediabetes 
versus normoglycemia [FPG < 5.6 mmol/L and 2hPG < 7.8 mmol/L and HbA1c < 5.7% (39 mmol/
mol)].
Approximately 36% of individuals met any of the ADA prediabetes criteria. Using 2hPG as the 
gold standard, the sensitivity of FPG was 40.1%, HbA1c was 45.6%, and that of HbA1c+FPG was 
62.2%. The number of significant PRs for cardiovascular risk factors was higher among 
individuals with isolated 2hPG = 7.8–11.1 mmol/L, FPG = 5.6–7.0 mmol/L + HbA1c = 
5.7%-6.4%, or those who met the three prediabetes criteria.
Assessing FPG, HbA1c, and cardiovascular risk factors in Hispanics/Latinos at risk might enhance 
the early prevention of diabetes mellitus and cardiovascular complications in this young and 
growing population, independent of their heritage group.
Keywords
Prediabetic state; Hispanics; Latinos; hypertension; obesity; LDL cholesterol; triglycerides
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Introduction
Prediabetes or increased risk of diabetes mellitus is a term that refers to early states of 
abnormal glucose homeostasis including impaired glucose tolerance (IGT) and impaired 
fasting glucose (IFG) [1,2]. IGT reflects inadequate postprandial insulin secretion [1,3], and 
is considered the earliest abnormality in glucose homeostasis that leads to the development 
of diabetes mellitus [3]. The oral glucose tolerance test (OGTT) detects IGT and is 
considered the gold standard test to detect diabetes mellitus [3]. IFG reflects increased 
hepatic glucose output, which leads to fasting hyperglycemia [2], and is assessed by fasting 
plasma glucose (FPG). Hemoglobin A1c (HbA1c) correlates directly with the preceding 2–3 
month-mean plasma glucose levels, and has been shown to be elevated during states of 
intermediate glucose homeostasis [2–8].
In 2010, the American Diabetes Association (ADA) recommended cut points for the 
diagnosis of diabetes mellitus and prediabetes based on FPG, OGTT, and HbA1c [9]. 
Although the tests and criteria recommended by the ADA are generally accepted, studies 
continue to report differences in sensitivity, variability, and reproducibility of HbA1c [2–8], 
FPG [3,10], and OGTT [11–15]. For instance, HbA1c has a direct association with glycemic 
levels, and has been shown to have a low intra-individual variability in the diabetes state [3]. 
However, some have reported that HbA1c has high inter-individual variability, and that its 
expected correlation with mean plasma glucose levels has not been observed among 
different racial/ethnic groups [3,10,16–18].
These observations are relevant to the clinical care of Hispanics/Latinos. Like the rest of the 
nation, they have experienced an increased prevalence of diabetes mellitus, and are 
considered a group at high risk of diabetes mellitus [19]. Given their diverse ethnic/racial 
and sociocultural backgrounds, it would be clinically useful to examine whether current 
ADA screening criteria for prediabetes are comparable for Hispanics/Latinos of different 
heritage groups.
The analyses presented in this manuscript describe the prevalence of prediabetes among 
adults from six different Hispanic/Latino heritage groups who participated in the Hispanic 
Community Health Study/Study of Latinos (HCHS/SOL) baseline examination. The 
prevalence of prediabetes was determined according to ADA diagnostic criteria across age, 
sex, and Hispanic/Latino heritage categories. The ability of FPG and HbA1c to identify 
Hispanic/Latino individuals with prediabetes was compared using the 2h-post oral load 
plasma glucose (2hPG)-obtained during the OGTT- as the gold standard. Previous studies 
have suggested that prediabetes is associated with an increased burden of cardiovascular risk 
factors and increased risk of coronary heart disease among Hispanics/Latinos from specific 
heritage groups [20,21]. Thus, we also assessed the prevalence of selected cardiovascular 
risk factors according to individual prediabetes criteria and their combinations.
Subjects, Materials, and Methods
The HCHS/SOL study design and sampling design have been published elsewhere [22,23]. 
Briefly, the HCHS/SOL is a longitudinal, population-based study whose objectives include 
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describing the prevalence of selected chronic diseases; identifying their risk and/or 
protective factors; and quantifying morbidity and mortality prospectively. From March 2008 
to June 2011, 16,415 persons, aged 18–74 years at the time of screening, who self-identified 
with Central American, Cuban, Dominican, Mexican, Puerto Rican, and South American 
heritage groups were examined. Participants were recruited following a multi-stage 
probability sampling of the communities in San Diego, California; Chicago, Illinois; Miami, 
Florida; and the Bronx, New York. The study was approved by each of the Field Center’s 
and the Coordinating Center’s Institutional Review Board. All enrolled individuals provided 
signed informed consent. Approximately 93% of participants completed all baseline 
interviews and tests.
Interviews (including sociodemographic information, self-identified Hispanic/Latino 
heritage group, family history of diabetes mellitus, place of birth, and years living in the 
U.S.), phlebotomy, processing of biospecimens, and anthropometric measurements 
[including body mass index (BMI)] were performed by trained and certified staff following a 
standard protocol [22]. Place of birth was defined as born in the U.S. mainland (born in any 
of the 50 states), or born outside of the U.S. mainland. Further detailed information is 
available at http://www.cscc.unc.edu/hchs. Participants were asked to consume only water 
and necessary medications after 10 p.m. the night before the baseline visit, and to refrain 
from smoking or physical activity before undergoing the fasting examination procedures. 
The examination of pregnant women was postponed until three months postpartum. 
Individuals with other chronic diseases or health conditions were not excluded from the 
study. All participants had FPG and HbA1c measured. After the initial venipuncture, those 
without self-reported diabetes mellitus and/or not taking antihyperglycemic medications 
and/or a FPG ≤ 8.4 mmol/L underwent a standard 75 g two-hour OGTT, and 2hPG was 
measured.
Plasma glucose, serum high-density lipoprotein-cholesterol (HDL-C), and serum 
triglycerides (TG) were measured using a Roche Modular P Chemistry Analyzer (Roche 
Diagnostics Corporation); urine albumin was measured using an immunoturbidometric 
method on the ProSpec nephelometric analyzer (Dade Behring GMBH, Marburg, Germany 
D-35041); and HbA1c concentration was measured in EDTA whole blood using a Tosoh G7 
Automated HPLC Analyzer. Low-density lipoprotein cholesterol (LDL-C) was not measured 
directly, but estimated using the Friedewald’s formula when TG < 4.5 mmol/L.
Definition of prediabetes states
Using ADA criteria [1,9], participants without self-reported diabetes mellitus, who were not 
taking antihyperglycemic medications, or who did not have laboratory tests within the 
diabetes range were classified as having prediabetes [IFG if FPG = 5.6–7.0 mmol/L; and/or 
IGT if 2hPG = 7.8–11.1 mmol/L; and/or impaired HbA1c if HbA1c = 5.7–6.4% (39–46 
mmol/mol)]; or as having normal glucose tolerance (NGT) [FPG < 5.6 mmol/L and 2hPG < 
7.8 mmol/L and HbA1c < 5.7% (39 mmol/mol)]. The total prevalence of prediabetes was 
defined as the percent of individuals who met at least one ADA diagnostic criterion.
A total of 16,415 individuals were enrolled and examined at baseline [24]. Individuals with 
missing diabetes mellitus screening laboratory data (n = 832), whose age was outside of the 
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selected range (n = 9), or who were taking antihyperglycemic medications and did not report 
having diabetes mellitus (n = 67) were not included in the analysis. A total of 15,507 
individuals had complete sets of relevant data for this analysis. Among these, 2,148 
individuals reported having physician-diagnosed diabetes mellitus and 1,194 had 
unrecognized diabetes mellitus [25], and were excluded from the analysis.
Definition of Cardiovascular Risk Factors
Selected cardiovascular risk factors were defined based on current national guidelines [26–
28]. Hypertension was defined as a systolic blood pressure ≥ 140 mm Hg, diastolic blood 
pressure ≥ 90 mm Hg, or receiving antihypertensive medications. Low HDL-C was defined 
as < 1.2 mmol/L in men and < 1.4 mmol/L in women; high LDL-C was defined as ≥ 3.4 
mmol/L; high TG were defined as ≥ 1.7 mmol/L; high urine albumin/creatinine ratio 
(UACR) was defined as > 30 mg/g; and obesity was defined as a BMI ≥ 30 kg/m2.
Statistical Analyses
All reported values were weighted by sampling weights using survey-specific procedures to 
account for the multi-stage sampling design, stratification, and clustering [29,30]. The 
sampling weights were calculated as the product of a “base weight” (reciprocal of the 
probability of selection) and three adjustments: (1) non-response adjustments made relative 
to the sampling frame, (2) trimming to handle extreme values (to avoid a few weights with 
extreme values being overly influential in the analyses), and (3) calibration of weights to the 
2010 U.S. Census according to age, sex, and Hispanic/Latino heritage group. The age, sex, 
and Hispanic/Latino heritage distributions based on the sampling weighted estimates were 
very similar to the Census 2010 population within the target recruitment areas, with size of 
the differences below 0.45% in the majority of cases.
Prevalence of total prediabetes and its individual criteria was age-standardized to the 2010 
U.S. Census population and reported as percentages with 95% confidence intervals (95% 
CI). Prevalence estimates were compared according to sex and age groups and Hispanic/
Latino heritage group using multilog modeling based Wald Chi square test. P-values were 
reported for the sex and age group comparisons and the overall comparison across Hispanic/
Latino heritage groups. A Venn diagram was constructed to illustrate the concordance and 
discordance among FPG-, HbA1c-, and 2hPG-based categories.
Marginal logistic regression models were used to estimate the sensitivity and specificity of 
the diagnostic criteria for prediabetes. The OGTT has long been recognized as the gold 
standard test for the detection of early abnormalities of glucose homeostasis. However, 
because clinical evaluation of prediabetes is now most often based on FPG or HbA1c, we 
were interested in comparing FPG, HbA1c, and the combination of FPG and HbA1c versus 
the 2hPG measured during the OGTT as the standard comparison. Age, sex, BMI, and 
Hispanic/Latino heritage group were added separately as covariates in the models to obtain 
strata-specific estimates of sensitivity and specificity.
We next examined the association between prediabetes and selected cardiovascular risk 
factors using separate Poisson regression models for each sex. In comparison with the 
reference group of NGT individuals, adjusted prevalence ratios (PRs) were estimated with 
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95% CI. The Taylor series linearization approach was used to compute robust estimates of 
standard errors for the regression coefficients and confidence intervals for the PRs [31,32]. 
Individual cardiovascular risk factors were modeled for five prediabetes glycemic categories: 
isolated IFG (individuals with IFG + normal 2hPG + normal HbA1c); isolated IGT 
(individuals with IGT + normal FPG + normal HbA1c); isolated Impaired HbA1c 
(individuals with Impaired HbA1c + normal FPG + normal 2hPG); IFG + Impaired HbA1c 
(individuals with IFG + Impaired HbA1c + normal 2hPG)], and IFG + IGT + Impaired 
HbA1c. These glycemic categories represent the spectrum of loss of glucose homeostasis in 
the prediabetes state. In addition, the first three categories represent different mechanisms of 
disease, and both FPG and HbA1c tests are commonly assessed in clinical settings. The first 
three categories did not overlap. All categories were adjusted for age and Hispanic/Latino 
heritage group. To determine whether Hispanic/Latino heritage group modified the 
association between individual cardiovascular risk factors and glycemic category, an 
interaction term was included in each model and assessed using the likelihood ratio test.
Statistical tests were two-sided at a significance level of 0.05. Adjustments for multiple 
comparisons were not made. All analyses were performed using SAS version 9.2 (SAS 
Institute Inc., Cary, NC), SUDAAN release 10.0.0 (Research Triangle Institute, Raleigh, 
NC), and Stata version 14 (StataCorp, LP, College Station, TX).
Results
Forty-five percent (45.0%) of the target population was classified as having NGT, and 36.3% 
met any of the three prediabetes criteria [Table 1]. The total prevalence of prediabetes and by 
individual criterion (or combinations) varied by age and sex. Total IFG was consistently 
higher in men across age groups. The prevalence of total prediabetes and individual criteria 
were consistently higher among individuals with BMI ≥ 30 kg/m2 compared to individuals 
with lower BMI. The prevalence of total prediabetes or individual criteria did not differ 
within each category of years living in the U.S. After stratifying by age group, the overall 
prevalence of prediabetes was similar between individuals born in the U.S. mainland born 
and those born outside of the U.S. mainland- aged 18–64 years- independent of years living 
in the U.S. [data not shown]. The prevalence of total prediabetes and its different criteria 
varied by Hispanic/Latino heritage group and between men and women within the same 
heritage group [Table 2]. Individuals of Dominican heritage had the lowest prevalence of 
prediabetes, total IFG, and total IGT. The prevalence of total Impaired HbA1c [Impaired 
HbA1c + (either normal FPG or IFG) + (either normal 2hPG or IGT)] and the combination 
of IFG + Impaired HbA1c, or the combination of IFG + IGT + Impaired HbA1c were similar 
among Hispanic/Latino heritage groups.
The concordance and discordance of the most prevalent prediabetes glycemic criteria or its 
combinations demonstrated that over a third of individuals – had isolated IFG, isolated IGT 
or isolated impaired HbA1c [Figure 1]. Using 2hPG as the gold standard, FPG and HbA1c 
showed low sensitivity and high specificity at detecting individuals within the prediabetes 
range overall and across Hispanic/Latino heritage groups [Table 3]. However, the sensitivity 
of the two tests combined increased, but the specificity decreased. The sensitivity of 
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individual and combined tests increased with age and BMI, and was consistently higher for 
men.
After adjusting for age and Hispanic/Latino heritage group, individuals who met all 
prediabetes glycemic criteria had higher prevalence of most cardiovascular risk factors 
[Table 4]. In addition, differences in the sex-specific prevalence of cardiovascular risk 
factors were observed. Overall, women had a greater prevalence of obesity and low HDL-C 
while men had a greater prevalence of high LDL-C and high TG across most glycemic 
categories.
Adjusted prevalence ratios of the selected cardiovascular risk factor were estimated 
separately for all men and women [Figures 2 and 3]. Because the overall prevalence of high 
UACR was low [Table 4], prevalence ratios were not estimated for this risk factor. Both men 
and women within each prediabetes category had significant prevalence ratios for obesity 
and high TG (except men with Isolated impaired HbA1c). Within the Isolated IFG, Isolated 
IGT, Isolated impaired HbA1c, and the IFG+IGT+Impaired HbA1c categories, the number of 
significant prevalence ratios varied between men and women. Both men and women with 
IFG+Impaired HbA1c+normal 2hPG or the three glycemic criteria had higher prevalence 
ratios than those in other categories.
Subgroup analyses showed that Hispanic/Latino heritage group significantly modified the 
association between isolated IFG and high TGs in women (P= 0.007) and obesity in men 
(P=0.037); Isolated IGT and hypertension in women (P=0.023) and high LDL-C in men 
(P=0.001); Isolated impaired HbA1c and low LDL-C in women (P=0.006); IFG + Isolated 
impaired HbA1c + normal 2hPG and low HDL-C (P=0.002) and obesity (P=0.026) in 
women; and the IFG + IGT + Impaired HbA1c and hypertension (P= 0.006), high TGs 
(P<0.001), and obesity (P=0.031) in women [data not shown]. The associations of IFG + 
isolated Impaired HbA1c + normal 2hPG and IFG + IGT + Impaired HbA1c with these 
cardiovascular risk factors were stronger among individuals of South American heritage 
[data not shown].
Discussion
Using the three diagnostic criteria for prediabetes recommended by the ADA, 36.3% of 
Hispanic/Latinos from six heritage groups met at least one criterion for prediabetes. The 
prevalence of total prediabetes and its glycemic subcategories varied among heritage groups. 
The combination of FPG and HbA1c was more sensitive, but less specific, than FPG or 
HbA1c alone at identifying individuals with prediabetes in every Hispanic/Latino heritage 
group. In addition, individuals with IFG and impaired HbA1c or who met the three glycemic 
criteria had a greater prevalence of cardiovascular risk factors than those with other 
prediabetes criteria.
Few studies have examined the prevalence of prediabetes and its diagnostic criteria among 
different Hispanic/Latino heritage groups in the U.S. In 1991, a report based on the Hispanic 
Health and Nutrition Examination Survey (Hispanic HANES) demonstrated differences in 
the prevalence of IGT among Mexican Americans, Cubans, and Puerto Ricans [33]. Other 
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reports have been based on the National Health Examination and Nutrition Survey 
(NHANES) [34,35] and the Insulin Resistance Atherosclerosis Study [6], in which 
Hispanics/Latinos are mostly or entirely of Mexican or Mexican-American descent. To the 
best of our knowledge, the analyses here presented constitute new data pertaining to 
identification of prediabetes that had not been described and compared before in a large 
sample of U.S. Hispanic/Latino adults of diverse heritage groups.
The latest estimate of the multivariable-adjusted prevalence of prediabetes in the U.S. overall 
population was 34.3% [95% CI, 32.7–35.9], and was based on IFG or HbA1c in the 5.7–
6.4% (39–46 mmol/mol) range measurements collected in the NHANES [34]. In the same 
report, the prevalence among Mexican-Americans in NHANES was 37.8% [95% CI, 33.9–
41.7]. The prevalence based on IFG or HbA1c in the 5.7–6.4% range in the entire 
HCHS/SOL sample was 30.7% [95% CI, 29.7–31.8], and 31.7% [95% CI, 29.9–33.5] 
among individuals of Mexican heritage [data not shown]. Differences between the NHANES 
and HCHS/SOL findings may be explained by differences in sampling methodology and 
weights, age standardization, and laboratory methodology, among other factors.
Some of the analyses presented in this manuscript demonstrate similarities to previous 
reports. The observed higher prevalence of IFG among men, and a tendency towards higher 
prevalence of IGT in women in HCHS/SOL have been previously reported in Hispanics/
Latinos and other populations [6,19,36–39]. Also, the observed low sensitivity of HbA1c as a 
sole test to detect prediabetes is consistent with previous analyses in Hispanics and non-
Hispanics [4,6]. Similarly, the increased sensitivity of HbA1c+FPG with increasing BMI, 
and the increased sensitivity of HbA1c+FPG compared to HbA1c alone observed in 
HCHS/SOL have been previously reported [7,8,35,39,40].
Conversely, some of our findings differ from previous reports. Contrary to previous studies 
[4,6,36], HbA1c in the range of 5.7%-6.4% (39–46 mmol/mol) was the most prevalent of the 
prediabetes criteria in HCHS/SOL. Approximately 85% of HCHS/SOL individuals with 
Isolated impaired HbA1c had HbA1c 5.7%-6.0% (39–42 mmol/mol), that is, in the lower 
level range [data not shown]. The high prevalence of Impaired HbA1c may be due in part to 
high intra-individual variability of HbA1c in the prediabetes state [3] or observed differences 
across heritage groups [41]. Also, hematologic factors known to alter HbA1c concentration –
such as hemoglobin variants, hemoglobinopathies, erythrocyte glucose uptake, hemoglobin, 
and serum iron levels– may explain elevated HbA1c levels, but these were either not 
examined in the HCHS/SOL or not included in these analyses.
Our findings also have some potential clinical applications. In our study, 23% of men and 
16% of women aged 18–29 years and 40% of men and 30% of women aged 30–39 years 
met at least one prediabetes criterion. Although the ADA recommended age cut point for 
screening for diabetes mellitus is 45 years [1,42] our data suggest that screening for diabetes 
mellitus in Hispanics/Latinos at a much younger age may identify individuals who would 
benefit from preventive interventions earlier in life. Using FPG and HbA1c –versus either 
test alone– would increase the chances of identifying those at higher risk. Since the 
prevalence of prediabetes was similar between U.S.-born and foreign-born Hispanics/
Latinos, independent on the number of years living in the U.S., we may expect that those 
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who have recently migrated would also benefit from earlier screening and interventions to 
prevent or delay diabetes mellitus, and that public health efforts to prevent diabetes mellitus 
are equally important abroad.
The association between some prediabetes glycemic abnormalities and the risk of 
developing diabetes mellitus or fatal and non-fatal cardiovascular disease (CVD) has been 
described in some Hispanic/Latino groups [13, 20, 43–48]. Non-glycemic cardiometabolic 
abnormalities may precede the onset of overt diabetes mellitus [21,49]. It has also been 
suggested that the burden of cardiometabolic abnormalities in the prediabetes state may 
explain the increased risk for CVD documented in women of Mexican descent with diabetes 
[21]. In our study, the prevalence of prediabetes glycemic categories varied across Hispanic/
Latino heritage groups. However, each prediabetes glycemic criteria or combination was 
associated with a significant prevalence of various cardiovascular risk factors in both men 
and women. Some of the associations between glycemic category and cardiovascular risk 
factors were modified by Hispanic/Latino heritage group, which may be partly attributed to 
variations in the duration of the glycometabolic dysregulation, anthropometric and 
nutritional characteristics, genetics, medications or comorbidities, among other factors. It is 
important to underline that future risk for the development of diabetes mellitus or CVD or 
how baseline risk factors relate to future CVD across Hispanic/Latino heritage groups 
cannot be fully determined through a cross-sectional analysis. And currently available 
cardiovascular risk score equations do not account the racial and ethnic heterogeneity of 
Hispanics/Latinos [50]. Since the HCHS/SOL has started a second examination the 
cardiovascular risk associated with each prediabetes criteria will be evaluated in the future.
Although the HCHS/SOL is not a nationally representative sample, the selected 
communities are located within four of the eleven U.S. metropolitan areas with the largest 
number of Hispanics/Latinos. Four of the five largest Hispanic/Latino heritage groups are 
represented in the study, with significant representation of other groups, thus reflecting the 
contemporary U.S. Hispanic/Latino population. The cohort’s large sample size and 
availability of FPG, OGTT, and HbA1c measurements provide adequate power for carrying 
out diverse cross-sectional analyses. Like in the NHANES [33,34], the prevalence of 
prediabetes in our cohort was assessed based on one set of laboratory tests. One-time 
measurements with potentially variable reliability and repeatability may lead to under- or 
overestimation of intermediate glycemic abnormalities [51]. Those who met only one of the 
three criteria would have needed confirmatory tests, as recommended by the ADA [1], but 
these were not performed in the study.
Conclusions
Over a third of adult U.S. Hispanics/Latinos from diverse heritage groups meet at least one 
ADA criterion of prediabetes, and the percent of those younger than age 45 merits attention. 
Since FPG, OGTT, and HbA1c represent different aspects of glucose homeostasis, 
performing more than one of these tests (at least FPG and HbA1c) and assessing other 
cardiovascular risk factors should be considered in the clinical evaluation of individuals at 
risk. Raising awareness on the effectiveness of a physically active lifestyle, improved 
nutrition and pharmacotherapy (when needed) in delaying the onset of diabetes [52], 
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working around individual and cultural paradigms influencing the success of these 
interventions, and exploring research opportunities to prevent diabetes mellitus and its 
complications in this young, diverse and growing population should continue.
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HIGHLIGHTS
• Over a third of U.S. Hispanic adults are at increased risk for diabetes mellitus.
• A significant percent of individuals younger than age 45 met prediabetes 
criteria.
• FPG plus HbA1c were more sensitive at detecting prediabetes than either test 
alone.
• Cardiovascular risk factors were highly prevalent across prediabetes 
categories.
• Cardiovascular risk factors were highly prevalent in both men and women.
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Figure 1. Venn Diagram of the Distribution of Pre-Diabetes Glycemic Criteria
The percentages are based on n = 15,507. (Baseline HCHS/SOL study data, 2008–2011) 
Total IFG = IFG + (either normal 2hPG or IGT) + (either normal or impaired HbA1c); Total 
IGT = IGT + (either normal FPG or IFG) + (either normal or impaired HbA1c); Total 
Impaired HbA1c = Impaired HbA1c + (either normal FPG or IFG) + (either normal 2hPG or 
IGT); Isolated IFG = IFG + normal 2hPG + normal HbA1c; Isolated IGT = IGT + normal 
FPG + normal HbA1c; Isolated HbA1c = Impaired HbA1c + normal FPG + normal 2hPG. 
The three main glycemic categories showed considerable overlap. Over half of individuals 
with Impaired HbA1c (57%), IFG (61%) and IGT (64%) had them combined with at least 
another glycemic abnormality. Almost 4% of the target population (or 10% of the population 
with prediabetes) met all three prediabetes glycemic criteria.
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Figure 2. Adjusted Prevalence Ratios of Selected Cardiovascular Risk Factors by Glycemic 
Category
Prevalence ratios were weighted and adjusted for age and Hispanic/Latino heritage group. 
(Baseline HCHS/SOL study data, 2008–2011).
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Figure 3. Adjusted Prevalence Ratios of Selected Cardiovascular Risk Factors by Glycemic 
Category
Prevalence ratios were weighted and adjusted for age and Hispanic/Latino heritage group. 
(Baseline HCHS/SOL study data, 2008–2011).
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